Logotype for BioAge Labs Inc

BioAge Labs (BIOA) investor relations material

BioAge Labs Q3 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for BioAge Labs Inc
Q3 2025 earnings summary6 Nov, 2025

Executive summary

  • Advanced BGE-102, an oral CNS-penetrant NLRP3 inhibitor, into Phase 1 SAD/MAD trials for obesity and cardiovascular risk, with first participant dosed and initial data expected by year-end 2025 and full results by mid-2026.

  • Terminated azelaprag program in January 2025 due to safety concerns, reallocating resources to BGE-102 and APJ agonist programs, including a nanobody with >10-fold potency over apelin.

  • Entered collaborations with Novartis and Lilly, recognizing $5.9M in revenue YTD, with potential for up to $550M in milestones and research funding.

  • Completed IPO and concurrent private placement in September 2024, raising $189.5M net proceeds.

  • Launched new APJ agonist nanobody program in partnership with JiKang Therapeutics.

Financial highlights

  • Collaboration revenue was $2.1M for Q3 2025 and $5.9M for the nine months ended September 30, 2025, compared to $0 in the prior year periods.

  • Net loss for Q3 2025 was $20.2M ($0.56 per share), a 14% improvement year-over-year; nine-month net loss was $54.7M.

  • Research and development expenses decreased 8% to $18.5M in Q3 2025, mainly due to the termination of azelaprag, but increased 24% to $49.5M for the nine months, driven by BGE-102 and APJ programs.

  • General and administrative expenses rose 41% to $6.7M in Q3 and 60% to $20.8M for the nine months, mainly due to higher stock-based compensation, legal, personnel, and insurance costs.

  • Cash, cash equivalents, and marketable securities totaled $295.9M as of September 30, 2025.

Outlook and guidance

  • Current cash and marketable securities are expected to fund operations and capital expenses through 2029.

  • Initial Phase 1 SAD data for BGE-102 expected by year-end 2025; full Phase 1 results by mid-2026; proof-of-concept trial top-line data anticipated in H2 2026.

  • IND filings for oral and parenteral APJ agonist programs targeted for year-end 2026.

  • Anticipates continued net operating losses as R&D and G&A expenses increase with clinical and preclinical program advancement.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next BioAge Labs earnings date

Logotype for BioAge Labs Inc
Jefferies London Healthcare Conference 202517 Nov, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next BioAge Labs earnings date

Logotype for BioAge Labs Inc
Jefferies London Healthcare Conference 202517 Nov, 2025

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

BioAge Labs Inc. is a biotechnology company focused on developing therapies to extend healthy human lifespan by targeting the biological pathways of aging. The company utilizes a proprietary platform that combines machine learning, genomics, and biomarker analysis to identify and develop drug candidates aimed at treating age-related diseases, such as those affecting muscle health, immune function, and metabolism. BioAge Labs conducts research to address the underlying biological factors of aging with the goal of improving health outcomes in later life. The company is headquartered in Richmond, California, and its shares are listed on the Nasdaq.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage